Key result
Prior prescription of vitamin K antagonists, but not DOACs, was associated with increased odds of symptomatic intracranial hemorrhage (aOR 2.55; 95% CI 1.35-4.84) after mechanical thrombectomy.
Why the study?
The safety and mortality after mechanical thrombectomy in patients receiving VKAs or DOACs remained to be determined.
Does prior VKA or DOAC use increase the risk of symptomatic intracranial hemorrhage and mortality in patients undergoing mechanical thrombectomy compared to no anticoagulation?
Cohort (n=1,932)
Yes
Does prior VKA or DOAC use increase the risk of symptomatic intracranial hemorrhage and mortality in patients undergoing mechanical thrombectomy compared to no anticoagulation?
Odds Ratio: 2.55 (95% CI 1.35–4.84)
Prior VKA use, but not DOAC use, is associated with an increased risk of symptomatic intracranial hemorrhage and mortality following mechanical thrombectomy for stroke.
No takes yet. Share an insight, caveat, or question.
Should not yet alter thrombectomy candidacy or anticoagulation choice; leaves open whether VKAs causally raise post-MT hemorrhage risk.
Meinel et al. (2020) conducted a cohort in Stroke (n=1,932). Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) vs. No anticoagulation was evaluated on Rate of symptomatic intracranial hemorrhage (sICH) and all-cause mortality at 90 days (aOR 2.55, 95% CI 1.35-4.84). Prior prescription of vitamin K antagonists, but not DOACs, was associated with increased odds of symptomatic intracranial hemorrhage (aOR 2.55; 95% CI 1.35-4.84) after mechanical thrombectomy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: